| | | Intervention | Endpoint | Average age(Years old) | Gender(%F) | Duration oftreatment | Samplesize | | Treatmentgroup | Controlgroup | Othergroup |
| | Reece, 2002 [16] | L | M | | ACR20 | L:60
M:61 | total:54 | 16 weeks | 39 | | Cohen, 2001 [17] | L | M | | ACR20, 50, 70 | L:54
M:53 | total:73 | 48 weeks | 380 | | Lv, 2015 [1] | T | M | M + T | ACR20, 50, 70 | T:51.3
M:51.0
M + T:50.6 | T:81.2
M:85.5
M + T:79.7 | 24 weeks | 207 | | Goldbach-mansky R,2009 [18] | S | T | | ACR20, 50, 70 | T:54
S:52 | T:73
S:87 | 24 weeks | 121 | | Strand，1994 [19] | L | M | P | ACR20, 50, 70 | L:54.1
M:53.3
P:54.6 | L:72.5
M:75.3
P:70.3 | 52 weeks | 482 | | Emery，2000 [20] | L | M | | ACR20 | L:58.3
M:57.8 | L:70.7
M:71.3 | 52 weeks | 999 | | Kraan，2000a [21] | L | M | | ACR20, 50 | L:60
M:59 | L:43.8
M:52.6 | 16 weeks | 35 | | Kraan，2000b [22] | L | M | | ACR20, 50 | L:63
M:66 | L:57.1
M:37.5 | 16 weeks | 15 | | Bao, 2003 [23] | L | M | | ACR20 | L:46.59
M:45.81 | L:81.1
M:79.8 | 12 weeks | 504 | | Capell, 2007 [24] | S | M | M + S | ACR20, 50, 70 | S:55
M:53
M + S:56 | S:75
M:79
M + S:75 | 48 weeks | 165 | | Haagsm, 1997 [25] | S | M | M + S | ACR20 | S:56.8
M:54.9
M + S:57.0 | S:61.8
M:65.7
M + S:66.7 | 52 weeks | 105 | | Dougads, 1999 [26] | S | M | M + S | ACR20 | S:52
M:50
M + S:52 | S:71
M:74
M + S:77 | 52 weeks | 205 | | Smolen, 1999 [27] | L | S | P | ACR 20, 50 | S:58.9
L:58.3
P:58.8 | S:69
L:76
P:75 | 24 weeks | 358 | | Karanikolas, 2006 [28] | C | L | L + C | ACR20, 50, 70 | — | — | 48 weeks | 102 | | Scott, 2001 [29] | L | S | | ACR20, 50, 70 | S:59
L:58 | S:69
L:76 | 24 weeks | 262 | | Yocum,2003 [30] | F | P | | ACR20, 50 | F:55.9
P:55.8 | F:77.2
P:75.8 | 24 weeks | 464 | | Kawai,2011 [31] | F | P | | ACR20, 50, 70 | F:47.1
P:50.0 | F:90.2
P:80.6 | 28 weeks | 123 | | Pillemer, 1997 [32] | Mi | P | | ACR20 | Mi:55.0
P:53.5 | Mi:76
P:80 | 48 weeks | 219 | | Chao-yang Long, 2019 [33] | T | M | | ACR20, 50 | T:65.03
M:64.79 | T:73.3
M:80.0 | 12 weeks | 60 | | Yong-qiang Wang, 2013 [34] | M | M + T | | ACR20, 50 | total:43.4 | total:55.6 | 12 weeks | 126 | | Ming-li Zhao, 2017 [35] | L + T | L | | ACR20, 50, 70 | L:62.24
L + T:64.32 | L:72.4
L + T:83.4 | 12 weeks | 68 |
|
|
TwHF, Tripterygium wilfordii Hook F; MTX, methotrexate; LEF, leflunomide; SSZ, sulfasalazine; CsA, cyclosporine; FK506, tacrolimus; and MINO, minocycline; M, MTX; T, TwHF; M + T, TwHF combined with MTX; L, LEF; L + T, TwHF combined with LEF; S, SSZ; M + S, SSZ combined with MTX; C, CsA; L + C, CsA combined with LEF; F, FK506; Mi, MINO; P, placebo.
|
